PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-positive cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Learn more about PDS Biotechnology
Please complete the form below to submit your registration request for the PDS Biotechnology Company Luncheon, to be held May 16,2024 in Miami, FL, presented by Noble Capital Markets. This meeting is open to qualified investors, and offered at no cost.
A representative will contact you, using the information you provide below, with more details on attending the event.
© 2023 Noble Capital Markets, Inc.
Noble Capital Markets, Inc. Members FINRA, SIPC, MSRB